Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

SOP for controlled copies for Contract Manufacturing, CRO and Global Outsourcing Models

Posted on By


SOP for Controlled Copies for Contract Manufacturing, CRO and Global Outsourcing Models

SOP for Controlled Copies for Contract Manufacturing, CRO and Global Outsourcing Models

This article details a comprehensive Standard Operating Procedure (SOP) for the management of controlled copies within the context of Contract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), and global outsourcing models in the pharmaceutical industry. This guidance aligns with GMP compliance, focusing on the standards set forth by regulatory bodies including the FDA, EMA, and MHRA. Following this SOP will significantly enhance your QA documentation and improve inspection readiness.

1. Objective

The objective of this SOP is to establish a uniform, compliant method for the distribution, control, and management of controlled copies of documents governing contract manufacturing and outsourcing operations. This SOP helps ensure data integrity and adherence to regulatory requirements, including Part 11 and Annex 11 compliance for electronic records.

See also  Aligning SOP for controlled copies With Data Integrity, ALCOA+ and 21 CFR Part 11

2. Scope

This procedure applies to all personnel engaged in the creation, distribution, and management of controlled document copies across all departments within the organization involved in collaboration with CMOs and CROs. It encompasses all document types that require controlled distribution, including but not limited to:

  • Manufacturing protocols
  • Validation documents
  • Standard Operating Procedures (SOPs)
  • Quality Assurance guidelines

3. Responsibilities

The following roles are designated responsibilities concerning controlled copies:

  • Document Control Specialist: Responsible for overseeing the controlled copy process, including managing records and ensuring compliance with regulatory standards.
  • Quality Assurance Manager: Ensures all procedures meet GMP compliance requirements and that all controlled document copies are audit-ready.
  • Department Heads: Responsible for ensuring that all personnel adhere to the requirements outlined in this SOP.

4. Definitions

For the purpose of this SOP, the following definitions will apply:

  • Controlled Copy: A copy of a document that is subject to formal rules regarding its creation, distribution, and revision. Only authorized individuals should have access to controlled copies.
  • Data Integrity: The accuracy and consistency of data stored in records, ensuring it remains trustworthy and valid across time.

5. Procedure

5.1 Document Creation

All controlled documents must be drafted in compliance with established templates that incorporate relevant regulatory requirements. The following steps must be taken for creating controlled documents:

  • Use the approved template for document types.
  • Ensure content meets the required guidelines and obtains necessary input from stakeholders.
  • Documents must be reviewed by at least two qualified individuals before approval.
See also  Building a Site-Wide SOP for controlled copies Roadmap for Continuous Improvement

5.2 Document Review and Approval

The review process is critical in maintaining document integrity and compliance. This process consists of:

  • Identification of reviewers: Select knowledgeable personnel within the relevant department.
  • Initiate review process: Distribute the draft document to the designated reviewers.
  • Collect feedback: Reviewers should submit feedback within the designated timeframe.
  • Document revisions: Incorporate all necessary changes and finalize the document for approval.
  • Final approval: Obtain sign-off from the Document Control Specialist and Quality Assurance Manager.

5.3 Distribution of Controlled Copies

Once approved, the distribution of controlled copies must follow stringent guidelines:

  • Controlled copies should be stamped as “Controlled Copy – Do Not Reproduce” before dissemination.
  • Maintain a master list of controlled copies distributed, including the date, recipient, and document version.
  • Distribute copies through secure methods to minimize the risk of unauthorized access.

5.4 Regular Review and Revision

Controlled documents must be reviewed on a regular basis to ensure they remain up-to-date and compliant. The following should be executed:

  • Set a review schedule aligned with regulatory changes, internal policies, or operational updates.
  • Use feedback from audits to make necessary revisions and proceed with the re-approval process.
  • Retain obsolete or superseded documents as per the company’s record retention policy, ensuring they are marked as “obsolete.”

5.5 Document Archiving

Once a document has been officially revised, all previous versions must be archived appropriately:

  • Utilize a secure electronic Document Management System (DMS) for archiving.
  • Ensure archived documents remain accessible for reference and audit purposes.
  • Enforce a policy for restricting access to archived documents to ensure data integrity.
See also  Digital SOP for controlled copies in eQMS, LIMS and MES Systems: Best Practices

6. Compliance and Audits

Compliance with this SOP is critical for maintaining readiness for inspections from regulatory bodies, such as the FDA, EMA, and MHRA. To ensure effective implementation:

  • Regularly schedule internal audits to evaluate adherence to SOP protocols.
  • Implement corrective and preventive actions (CAPA) based on audit findings.
  • Conduct training sessions for relevant personnel to reinforce understanding and compliance.

7. Training Requirements

All personnel involved in the handling of controlled copies must undergo training to ensure understanding of SOP requirements:

  • Provide initial training upon onboarding and regular refresher courses.
  • Ensure training materials are up to date and include practical examples of compliance.
  • Document all training sessions as part of quality assurance documentation.

8. References

This SOP is informed by regulatory guidelines and standards as outlined by several prominent organizations:

  • World Health Organization (WHO)
  • PIC/S
  • ICH Guidelines for Good Clinical Practice

9. Conclusion

By following this comprehensive SOP for the management of controlled copies, organizations can significantly enhance their regulatory compliance and data integrity efforts. Keeping abreast of the latest regulatory guidelines and maintaining meticulous documentation will facilitate smooth operations and readiness for inspections by the FDA, EMA, and MHRA.

In conclusion, a well-crafted SOP for controlled copies not only protects the organization but also ensures that quality standards are met across all phases of pharmaceutical and clinical operations. For institutions focused on establishing a robust Quality Management System (QMS), this SOP acts as an essential tool for compliance and integrity.

SOP for controlled copies Tags:Data Integrity, EMA, FDA, GMP compliance, MHRA, Part 11, QA, regulatory affairs, SOP

Post navigation

Previous Post: Common Errors in SOP for controlled copies Cited in Regulatory Inspections and How to Fix Them
Next Post: Digital SOP for controlled copies in eQMS, LIMS and MES Systems: Best Practices

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version